PubMed Journals Articles About "PErsonalized TREatment Of High-risk MAmmary Cancer - The PETREMAC Trial" RSS

02:53 EST 14th December 2019 | BioPortfolio

PErsonalized TREatment Of High-risk MAmmary Cancer - The PETREMAC Trial PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest PErsonalized TREatment Of High-risk MAmmary Cancer - The PETREMAC Trial articles that have been published worldwide.

More Information about "PErsonalized TREatment Of High-risk MAmmary Cancer - The PETREMAC Trial" on BioPortfolio

We have published hundreds of PErsonalized TREatment Of High-risk MAmmary Cancer - The PETREMAC Trial news stories on BioPortfolio along with dozens of PErsonalized TREatment Of High-risk MAmmary Cancer - The PETREMAC Trial Clinical Trials and PubMed Articles about PErsonalized TREatment Of High-risk MAmmary Cancer - The PETREMAC Trial for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PErsonalized TREatment Of High-risk MAmmary Cancer - The PETREMAC Trial Companies in our database. You can also find out about relevant PErsonalized TREatment Of High-risk MAmmary Cancer - The PETREMAC Trial Drugs and Medications on this site too.

Showing "PErsonalized TREatment High risk MAmmary Cancer PETREMAC Trial" PubMed Articles 1–25 of 77,000+

Risk Estimation, Anxiety and Breast Cancer Worry in Women at Risk for Breast Cancer: A Single-Arm Trial of Personalized Risk Communication.

Elevated anxiety and breast cancer worry can impede mammographic screening and early breast cancer detection. Genetic advances and risk models make personalized breast cancer risk assessment and communication feasible, but it is unknown whether such communication of risk affects anxiety and disease-specific worry. We studied the effect of a personalized breast cancer screening intervention on risk perception, anxiety and breast cancer worry.

Dose-dependent effect of aerobic exercise on inflammatory biomarkers in a randomized controlled trial of women at high risk of breast cancer.

Increased levels of inflammation are associated with many diseases, including cancer. Physical activity can lower breast cancer risk as well as levels of inflammation. The Women In Steady Exercise Research (WISER) Sister trial was a randomized controlled trial that investigated the effects of a dosed, moderate to vigorous, aerobic exercise intervention on levels of inflammation in premenopausal women who were at high risk of developing breast cancer.

Airborne mammary carcinogens and breast cancer risk in the Sister Study.

Potentially carcinogenic hazardous air pollutants (air toxics) have been inconsistently associated with breast cancer. Whether metabolic factors modify these associations is unknown. We studied 29 non-metallic air toxics classified as mammary gland carcinogens in animal studies in relation to breast cancer risk.

Personalized E-Coaching in Cardiovascular Risk Reduction: A Randomized Controlled Trial.

To assess whether electronic (e-) coaching, using personalized web-based lifestyle and risk factor counselling with additional email prompts, provides additional risk reduction when added to standard of care (SOC) in individuals at increased risk.

Latent Profiles of Cognitive and Interpersonal Risk Factors for Adolescent Depression and Implications for Personalized Treatment.

A personalized approach to treatment with patients being matched to the best-fit treatment has been proposed as one possible solution to the currently modest treatment response rates for adolescent depression. Personalized treatment involves identifying and characterizing subgroups likely to respond differently to different treatments. We investigated the feasibility of this approach, by focusing on two key risk factors that are the purported treatment targets of cognitive behavioral therapy (CBT) and inter...

Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes.

Often unrecognized and underdiagnosed, myelodysplastic syndromes (MDS) are a rare group of cancers in which the bone marrow fails to produce sufficient healthy blood cells. Although patients with lower-risk MDS can live for >5 years, those with high-risk disease that evolves into acute myeloid leukemia is associated with significantly lower overall survival. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Rafael Bejar summarized current standard treatment options for patients with MDS and di...

Precision Oncology: Three Small Steps Forward.

Only a subset of cancer patients currently benefit from personalized treatment approaches. Detection of actionable drug targets in cell-free DNA, more comprehensive molecular profiling integrating transcriptional analyses, and personalized combination regimens all hold promise in expanding the benefits of personalized oncology to larger numbers of cancer patients.

The Eleventh ENBDC Workshop: Advances in Technology Help to Unveil Mechanisms of Mammary Gland Development and Cancerogenesis.

The eleventh annual workshop of the European Network for Breast Development and Cancer, Methods in mammary gland biology and breast cancer, took place on the 16th to 18th of May 2019 in Weggis, Switzerland. The main topics of the meeting were high resolution genomics and proteomics for the study of mammary gland development and cancer, breast cancer signaling, tumor microenvironment, preclinical models of breast cancer, and tissue morphogenesis. Exciting novel findings in, or highly relevant to, mammary gla...

Ultra-Hypofractionated Radiation Therapy for Unfavorable Intermediate-Risk and High-Risk Prostate Cancer is Safe and Effective: 5-year Outcomes of a Phase II Trial.

To report toxicity (primary endpoint) and biochemical disease-free survival (BDFS) outcomes of a phase II trial evaluating ultra-hypofractionated radiation therapy (UHRT) focusing on unfavorable intermediate-risk (UIR) and high-risk (HR) prostate cancer (PCa) patients.

Personalized Care in the Prevention of Treatment-Related Cardiac Dysfunction in Female Cancer Survivors.

The American Cancer Society projects the number of U.S. cancer survivors to exceed 20 million individuals by 2026. However, approximately one in four cancer survivors report decreased quality of life due to physical dysfunction and disabling symptoms. Many effective anticancer treatments are now understood to be associated with cardiotoxicity, such that, for many survivors, the risk of death from cardiovascular disease now exceeds that of recurrent cancer. We undertook a Clinical Review of cancer treatment...

Function of ion transporters in maintaining acid-base homeostasis of the mammary gland and the pathophysiological role in breast cancer.

The incidence of breast cancer is increasing year by year, and the pathogenesis is still unclear. Studies have shown that the high metabolism of solid tumours leads to an increase in hypoxia, glycolysis, production of lactic acid and carbonic acid, and extracellular acidification; a harsh microenvironment; and ultimately to tumour cell death. Approximately 50% of locally advanced breast cancers exhibit hypoxia and/or local hypoxia, and acid-base regulatory proteins play an important role in regulating milk ...

Risks and Benefits of Anticoagulation in Cancer and Noncancer Patients.

Venous thromboembolism (VTE) is a common complication of cancer occurring in up to one-fifth of cancer patients. The risk of VTE, which includes deep venous thrombosis (DVT) and pulmonary embolism (PE), is increased up to seven-fold in patients with cancer. While the indications and contraindications to treatment for VTE patients with cancer parallel to those patients without cancer, the treatment of VTE is challenging for cancer patients who are three-fold more likely to have VTE recurrence than patients w...

Microfluidics for personalized drug screening of cancer.

Resistance to targeted therapies is a major clinical challenge in cancer treatment. Despite technological advances, robust biomarkers or platforms predictive of treatment response are lacking owing to the inherent nature of complex genomic landscape of carcinoma. Nevertheless, recent efforts centred on performing direct drug screening on patient-derived cells through their ex vivo expansion and maintenance have enabled personalized stratification of treatment modalities. Microfluidics is one such technology...

An update on risk assessment for familial and hereditary colorectal cancer.

Family history risk assessment can identify individuals at increased risk of colorectal cancer (CRC) who would benefit from earlier or more frequent CRC screening. Clinicians should evaluate the patient's family history as well as personal history to identify red flags and patterns that may suggest predisposition to CRC and then use that information to stratify risk into average, increased, and high risk categories to inform genetic counseling recommendations and personalized management.

Redirecting Normal and Cancer Stem Cells to a Mammary Epithelial Cell Fate.

Tissue microenvironments, also known as stem cell niches, influence not only resident cells but also cells in surrounding tissues. Physical and biochemical intercellular signals originating from resident stem cells or non-stem cells participate in the homeostasis of the tissue regulating cell proliferation, differentiation, wound healing, tissue remodeling, and tumorigenesis. In recent publications it has been demonstrated that the normal mouse mammary microenvironment can provide development and differenti...

Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy for Clinically Localized, High - Risk Prostate Cancer.

Approximately 15% of men with newly diagnosed prostate cancer have high-risk features that increase the risk of recurrence and metastasis. Better predictive biomarkers could allow for earlier detection of biochemical recurrence (BCR) and change surveillance and adjuvant treatment paradigms. Circulating tumor cells (CTCs) are thought to represent the earliest form of metastases, however their role as biomarkers in men with high-risk localized prostate cancer (HRLPCa) is not well defined.

Screening Guidelines Update for Average-Risk and High-Risk Women.

The purpose of this study is to describe screening updates for women with average and high risk for breast cancer, compare different screening strategies, and describe new approaches in risk prediction, including radiomics. All women are at substantial risk for breast cancer. For women with average risk, annual mammography beginning at 40 years old maximizes the life-extending benefits and provides improved treatment options. Women at higher risk need earlier and more intense screening. Delaying initiation...

A personalized, web-based breast cancer decision making application: a pre-post survey.

Every case of breast cancer is unique, and treatment must be personalized to incorporate a woman's values and preferences. We developed an individually-tailored mobile patient education application for women with breast cancer.

HPV Testing for Cervical Cancer in Romania: High-Risk HPV Prevalence among Ethnic Subpopulations and Regions.

Romania has had one of the highest rates of cervical cancer incidence and mortality in Europe for decades. Data on the high-risk human papillomavirus (hrHPV) prevalence within the Romanian population are crucial for cervical cancer intervention in high risk groups. The aim of this study was to determine the prevalence of hrHPV infection in Romania, identifying high-risk areas for cervical cancer prevention efforts.

Mammographic screening in male patients at high risk for breast cancer: is it worth it?

To investigate the utility of mammography for breast cancer screening in a population of males at increased risk for breast cancer.

Time patterns of recurrence and second primary tumors in a large cohort of patients treated for oral cavity cancer.

Routine follow-up after curative treatment of patients with oral squamous cell carcinoma (OSCC) is common practice considering the high risk of second primaries and recurrences (ie second events). Current guidelines advocate a follow-up period of at least 5 years. The recommendations are not evidence-based and benefits are unclear. This is even more so for follow-up after a second event. To facilitate the development of an evidence- and personalized follow-up program for OSCC, we investigated the course of...

Towards integrating personalized feedback research into clinical practice: Development of the Trier Treatment Navigator (TTN).

In this study, a computer-based feedback, decision and clinical problem-solving system for clinical practice will be described - the Trier Treatment Navigator (TTN). The paper deals with the underlying research concepts related to personalized pre-treatment recommendations for drop-out risk and optimal treatment strategy selection as well as personalized adaptive recommendations during treatment. The development sample consisted of 1234 patients treated with cognitive behavioral therapy (CBT). Modern statis...

Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients.

Epidemiologic and preclinical data suggest a potential role for vitamin D in breast cancer treatment and prevention. However, results of prospective randomized trials are inconsistent. The objective of this study was to assess the effects of high-dose cholecalciferol (vitamin D3) on breast tumour proliferation and apoptosis.

Personalized Therapy In Osteoporosis.

In Germany, over six million people suffer from osteoporosis. Nearly half of the women over 70 years and nearly 20 % of men at the same age are affected. The clinical and socioeconomical relevance of the disease lies in osteoporotic fractures leading to extensive bone-associated morbidity, increased mortality and health care costs. Fracture risk algorithms and guidelines for the diagnosis and treatment of osteoporosis help to assess the individual fracture risk. By calculating the individual fracture risk...

High-Intensity Interval Training is Feasible in Women at High Risk for Breast Cancer.

This trial aimed to demonstrate feasibility of high-intensity interval training (HIIT) in post-menopausal, overweight/obese women at high-risk of invasive breast cancer, and explore HIIT on changes in cardiorespiratory fitness (CRF), body weight, and body mass index (BMI) compared to moderate-intensity continuous training (MICT) and usual care (UC).

Quick Search